Intranasal Drug Delivery (Allergic Infections, Analgesics, Osteoporosis, and Vaccinations.)

Intranasal Drug Delivery (Allergic Infections, Analgesics, Osteoporosis, and Vaccinations.)

This report analyzes the US Market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 64 companies including many key and niche players such as -

Aegis Therapeutics LLC
AptarGroup, Inc.
AstraZeneca Plc
Becton Dickinson and Company
GlaxoSmithKline Plc
Johnson & Johnson Inc.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Study Reliability and Reporting Limitations
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study
A Prelude
Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
Factors Inhibiting Nose-to-Brain Transportation of Drugs
Drug’s Physico-Chemical Properties
Drug Dose, Concentration & Volume Administration
Mucociliary Clearance
Existence of Enzymatic Activity
Animal Species: Variations in Nasal Mucosa
Overcoming Barriers to Nose-to-Brain Delivery of Drugs
Prodrug Technique
Innovative Formulation
Use of Enzyme Inhibitors & Absorption Enhancers
Bioavailability: An Important Facet of Intranasal Drug Delivery
Chemical Modification
Transient Modification & Limited Enzymatic Activity
Bioavailability of Large Molecules
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
Nasal Drug Delivery Devices & Equipment
Preservative Free Systems (PFS)
Traditional Vs. Advanced Intranasal Drug Formulation Types
Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application
Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
Table 1: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
Table 2: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2010, 2015 & 2020 (includes corresponding Graph/Chart)
Table 3: Global Aging Population (in Thousands) by Age Group: 2010, 2015, 2025 & 2050 (includes corresponding Graph/Chart)
Table 4: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2015 (includes corresponding Graph/Chart)
Table 5: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
Table 6: Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart)
Table 7: US Geriatric Population by Age Group (2000, 2005, 2010, 2015, 2020, 2030, 2040, & 2050): Percentage Share of US Population of Senior Citizens of Age Group 65-74 Years, 75- 84 Years, and 85 Years & Above (includes corresponding Graph/Chart)
Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
Table 8: Top Nasal Inhalers, Sprays, and Drops Brands in the US (2017): Percentage Share Breakdown of Dollar Sales for Afrin No Drip, Afrin, Arm & Hammer Simply Saline, Zicam, Neilmed Sinus Rinse, Ayr, Private Labels, and Others (includes corresponding Graph/Chart)
Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
Table 9: Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries: 2016 (includes corresponding Graph/Chart)
Table 10: The US Allergic Rhinitis Patient Population by Disease Severity (2016): Percentage Breakdown of Patient Pool for Mild Intermittent, Mild Persistent, Moderate-severe Intermittent, and Moderate-severe Persistent (includes corresponding Graph/Chart)
The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
Table 11: Global Respiratory Drugs Market by Category (2015 & 2020): Percentage Breakdown of Dollar Values for COPD Therapies, Inhaled Steroids, Long Acting Beta Agonists, Nasal Steroids, and Others (includes corresponding Graph/Chart)
The US - FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
The US - FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
Intranasal Corticosteroids – A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
Innovation in Drug Delivery: A Talisman for Success
Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
Controlled Release Technology Is the Buzz Word
Target-Specific Delivery Devices: Of Critical Value
Safety and Cost: Primary Growth Drivers
Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
Intranasal Therapeutics Delivery – A High Potential Method for Treating CNS Diseases
Intranasal Insulin Delivery Offers Strong Clinical Significance
Inhaled Insulin Market Challenged by Low Acceptance Levels
Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents
Intranasal Delivery of Peptide-Based Pharmaceuticals
Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
Tight Junction Biology: A Key Speed Breaker in Commercialization
RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery
Growing Interest for Preservative-free Nasal Spray Formulations
Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination
Nose-to-Brain Drug Delivery
– A Potential Alternative for Many Brain Disorders
Orexin-A Replacement for Treating Nacrolepsy
Advanced Nanoparticle Nasal Spray to Enable Drug Delivery to Brain
OptiNose Develops Innovative Treatment Option for Sinusitis
Intranasal Administration of ATX-LIPO for Brain Targeting – A Promising Therapy for ADHD
Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics
Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery
Evoke Pharma Develops
Intranasal Metoclopramide Delivery System for Treating Gastroparesis
Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery
Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs
Select Nasal Drug Absorption Enhancers and Related Mechanisms
Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration
Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications
OptiNose ONZETRA Xsail (
) – An Innovative Breath-Powered Intranasal Delivery System for Migraine Treatment
Clinical Study Demonstrates Faster Antidepression Effects of Intranasal Ketamine
Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD)
Intranasal Drug Delivery: A Descriptive Exposition
Nasal Physiology
Challenges Involved In Formulating Nasal Drugs
The Importance of Bioadhesion
Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
Intranasal Drugs – Prescription (Rx) and Over-the-Counter (OTC)
Differences between Systemic Delivery and Local Effects
Nasal Powders Vs. Sprays
Nasal Drug Delivery Devices
Types of Drug Delivery Devices
Aerosol Containers/Inhalers
Nasal Aspirators
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques
Limitations of Intranasal Drug Delivery
Allergic Rhinitis
Nasal Allergies
Nasal Drugs for Allergies
Corticosteroid Nasal Sprays
Other Nasal Corticosteroid Drugs
Antihistamine Nasal Sprays
Astelin Nasal Spray
Otrivin Nasal Spray
Livostin Nasal Spray
Other Nasal Antihistamine Drugs
Select Brands of Allergy Relievers
Nasal Drugs for Postmenopausal Osteoporosis
Calcitonin–Salmon Nasal Spray
Miacalcin Nasal Spray
Fortical® Nasal Spray
Intranasal Pain Management Drugs
Stadol Nasal Spray
Zolmitriptan Nasal Spray
Intranasal Analgesics for Treating Migraine
Intranasal Vaccination
Process of Intranasal Immunization
"LAIV" Nasal Spray Flu Vaccine
FluMist® Vaccine from MedImmune
Intranasal Drugs for Sexual Dysfunction
Nasal Spray for Treating Vitamin B12 Deficiency
Nasal Spray for Aiding Smoking Cessation
FDA Approves OptiNose XHANCE™ Nasal Spray
Splintek Launches Intra-Nasal Sleep Inhaler
Allergan Receives Market Authorization for TrueTear™
St. Renatus Launches Kovanaze™ Nasal Spray
Perrigo and West-Ward Pharmaceuticals Launch Generic Store Brand Flonase®
Nemera Launches Advancia Multi-Dose Nasal Spray System
Adapt Pharma Launches Narcan Opioid Antagonist
Apotex Unveils Generic Version of Nasonex®
McNeil Consumer Healthcare Rolls Out OTC RHINOCORT®
OptiNose Bags FDA Approval for ONZETRA™ Xsail™
Avanir’s Onzetra Secures FDA Approval
FDA Approves Lannett’s Sumatriptan Nasal Spray
Meda’s Dymista Bags Health Canada’s Approval
Endo Pharmaceuticals Announces Availability of NATESTO
AstraZenca Canada Unveils FluMist for Children
Perrigo Receives US FDA Approval for Generic Version of Sun Pharma's Kenalog
GSK Rolls Out OTC Version of Flonase Allergy Relief
Upsher-Smith Publishes Data from USL261 Phase 1 Trials
KemPharm Concludes KP201/APAP’s Human Abuse Liability Program
OptiNose Publishes Results of OPN 375’s Phase III Trial
NanoBio’s Genital Herpes Vaccine Proven Effective
Recro Pharma Releases Further Details of Dex-IN’s Phase II Clinical Trial
Evoke Announces Phase III Trials of
FDA Accepts Filing of TARSA’s TBRIA
FDA Accepts Review of Pfizer’s
Breckenridge Bags FDA Approval for Azelastine HCl Nasal Solution
ZOMIG® Gets FDA Approval
Opiant Pharmaceuticals to Pursue Development of Intranasal Nalmefene
Egalet and OraPharma to Co-Promote SPRIX Nasal Spray
Aegis Develops Hydromorphone Nasal Spray
Emergent Biosolutions to Develop Intranasal Spray for Treatment of Cyanide Poisoning
Aptar Pharma to Manufacture Child-Resistant Nasal Pumps in North America
Therapix and Yissum Sign License for Cannabinoid Nasal Drug Delivery Technology
Impel NeuroPharma and Camargo Pharmaceutical Services Sign Service Agreements
Egalet Inks Deal With Septodont for SPRIX® Promotion
Lilly Acquires Intranasal Glucagon Rights
UAE recalls Otrivin Nasal Spray Batches
Eli Lily Acquires Rights for Innovent’s Intranasal Glucagon
AstraZenca Commences Shipment of FluMist®
Aegis Therapeutics LLC (USA)
AptarGroup, Inc. (USA)
AstraZeneca Plc. (UK)
MedImmune, Inc. (USA)
Becton Dickinson and Company (USA)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson Inc. (USA)
Marina Biotech, Inc. (USA)
Merck & Co., Inc. (USA)
Nemera (France)
Novartis AG (Switzerland)
OptiNose US Inc. (USA)
Pfizer, Inc. (USA)
Valeant Pharmaceuticals International, Inc. (Canada)
Table 12: The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
Table 13: The US Historic Review for Intranasal Drug Delivery by Therapeutic Area - Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
Table 14: The US 14-Year Perspective for Intranasal Drug Delivery by Therapeutic Area - Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
III. COMPETITIVE LANDSCAPE Total Companies Profiled: 64 (including Divisions/Subsidiaries - 81)
The United States (48)
Canada (4)
Japan (2)
Europe (17)
- France (2)
- Germany (4)
- The United Kingdom (4)
- Rest of Europe (7)
Asia-Pacific (Excluding Japan) (7)
Middle East (2)
Latin America (1)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook